API | indobufen

indobufen Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Now

Indobufen is a platelet aggregation inhibitor. It acts as a reversible cyclooxygenase inhibitor. ^Wikipedia

Chemistry

SMILES: CCC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1
InChIKey: AYDXAULLCROVIT-UHFFFAOYSA-N
Mol. Mass: 295.34
ALogP: 3.43 Partition coefficient
ChEMBL Molecule:
indobufen

More Chemistry

Pharmacology

Mechanism of Action:
- Prostaglandin G/H synthase 1 (Homo sapiens) ^UniProt
- Prostaglandin G/H synthase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(4-(1-oxo-2-isoindolinyl)phenyl)butyric acid | 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl) alpha- ethylbenzeneacetic acid | ibustrin | indobufen | indobufen, (+-)-isomer | k 3920 | k-3920

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (1)

Coronary Artery Disease

Experimental Indications - Clinical Trial Phases 1-4 (8)

Aspirin (Phase 4)

Atrial Fibrillation (Phase 3)

Coronary Artery Disease (Phase 4)

Drugs, Investigational (Phase 4)

Gastroesophageal Reflux (Phase 4)

Healthy Volunteers (Phase 1)

Ischemic Stroke (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue